Skip to main content

Advertisement

Table 3 Breast cancer incidence in pre-, peri/postmenopausal and all women in relation to serum T3 levels

From: Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women

Group T3
(quartile)
Individuals
(n)
Breast cancer
cases
(n)
Person-years Incidence/100,000 All cases Cases >3 years following
Baseline examination
       RR
(CI: 95%)
RR**
(CI: 95%)
RR
(CI: 95%)
RR**
(CI: 95%)
All 1 494 28 10,418 269 1.00 1.00 1.00 1.00
  2 704 40 14,613 274 1.02 (0.63 to 1.66) 1.12 (0.69 to 1.84) 1.10 (0.66 to 1.83) 0.99 (0.60 to 1.66)
  3 456 31 9,096 341 1.28 (0.77 to 2.13) 1.42 (0.83 to 2.43) 1.37 (0.78 to 2.42) 1.21 (0.70 to 2.10)
  4 531 47 10,091 466 1.75 (1.10 to 2.80)* 1.87(1.12 to 3.14)* 1.98 (1.15 to 3.38)* 1.78 (1.10 to 2.90)*
  P-trend      0.007 0.009 0.007 0.008
Premenopausal 1 298 25 6,376 392 1.00 1.00 1.00 1.00
  2 311 21 6,621 317 0.81 (0.45 to 1.45) 1.00 (0.55 to 1.81) 1.00 (0.53 to 1.87) 0.80 (0.43 to 1.46)
  3 131 7 2,816 249 0.63 (0.27 to 1.47) 0.71 (0.30 to 1.70) 0.79 (0.33 to 1.91) 0.69 (0.33 to 1.61)
  4 123 9 2,610 345 0.88 (0.41 to 1.88) 0.92 (0.40 to 2.15) 1.07 (0.45 to 2.50) 0.96 (0.44 to 2.10)
  P-trend      0.49 0.66 0.94 0.99
Peri/post-menopausal 1 196 3 4,042 74 1.00 1.00 1.00 1.00
  2 393 19 7,992 237 3.24 (0.96 to 10.9) 3.26 (0.96 to 11.1) 2.75 (0.80 to 9.48) 2.90 (0.85 to 9.91)
  3 325 24 6,281 382 5.21 (1.57 to 17.4)* 5.53 (1.65 to 18.6)* 4.63 (1.35 to 15.8)* 4.39 (1.30 to 14.8)*
  4 408 38 7,481 508 6.94 (2.14 to 22.5)* 6.87 (2.09 to 22.6)* 6.14 (1.86 to 20.3)* 6.49 (1.99 to 21.1)*
  P-trend      <0.001 <0.001 <0.001 <0.001
  1. Abbreviations: T3, triiodothyronine; RR, relative risk; RR**, relative risk adjusted for age (continuous), menopausal status (in analysis of all women), use of HRT, nulliparity, use of oral contraception, age at menarche, smoking status, alcohol consumption, BMI, height, educational level and marital status, * P < 0.05.